Effects of sex hormones on vascular reactivity in boys with hypospadias.

Testosterone androgen dihydrotestosterone estrogen vessel

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
06 Sep 2023
Historique:
received: 11 01 2023
revised: 23 08 2023
accepted: 31 08 2023
medline: 6 9 2023
pubmed: 6 9 2023
entrez: 6 9 2023
Statut: aheadofprint

Résumé

Arteries from boys with hypospadias demonstrate hypercontractility and impaired vasorelaxation. The role of sex hormones in these responses in unclear. We compared effects of sex steroids on vascular reactivity in healthy boys and boys with hypospadias. Excess foreskin tissue was obtained from 11 boys undergoing hypospadias repair (cases) and 12 undergoing routine circumcision (controls) (median age (range) 1.5 (1.2, 2.7) yrs) and small resistance arteries were isolated. Vessels were mounted on wire myographs and vascular reactivity was assessed in the absence/presence of 17β-estradiol, dihydrotestosterone (DHT) and testosterone. In controls, testosterone and 17β-estradiol increased contraction (Emax: 83.74 basal vs 125.4 after testosterone, p < 0.0002 and 83.74 vs 110.2 after estradiol, p = 0.02). 17β-estradiol reduced vasorelaxation in arteries from controls (Emax: 10.6 vs 15.6 to acetylcholine (ACh), p < 0.0001 and Emax: 14.6 vs 20.5 to sodium nitroprusside (SNP), p < 0.0001). In hypospadias, testosterone (Emax: 137.9 vs 107.2, p = 0.01) and 17β-estradiol (Emax: 156.9 vs 23.6, p < 0.0001) reduced contraction. Androgens, but not 17β-estradiol, increased endothelium-dependent and endothelium-independent vasorelaxation in cases (Emax: 77.3 vs 51.7 with testosterone, p = 0.02 and vs 48.2 with DHT to ACh, p = 0.0001; Emax: 43.0 vs 39.5 with testosterone, p = 0.02 and vs 39.6 vs 37.5 with DHT to SNP, p = 0.04). In healthy boys, testosterone and 17β-estradiol promote a vasoconstrictor phenotype whereas in boys with hypospadias, these sex hormones reduce vasoconstriction, with androgens promoting vasorelaxation. Differences in baseline artery function may therefore be sex hormone independent and the impact of early-life variations in androgen exposure on vascular function needs further study.

Sections du résumé

BACKGROUND BACKGROUND
Arteries from boys with hypospadias demonstrate hypercontractility and impaired vasorelaxation. The role of sex hormones in these responses in unclear.
AIMS OBJECTIVE
We compared effects of sex steroids on vascular reactivity in healthy boys and boys with hypospadias.
METHODS METHODS
Excess foreskin tissue was obtained from 11 boys undergoing hypospadias repair (cases) and 12 undergoing routine circumcision (controls) (median age (range) 1.5 (1.2, 2.7) yrs) and small resistance arteries were isolated. Vessels were mounted on wire myographs and vascular reactivity was assessed in the absence/presence of 17β-estradiol, dihydrotestosterone (DHT) and testosterone.
RESULTS RESULTS
In controls, testosterone and 17β-estradiol increased contraction (Emax: 83.74 basal vs 125.4 after testosterone, p < 0.0002 and 83.74 vs 110.2 after estradiol, p = 0.02). 17β-estradiol reduced vasorelaxation in arteries from controls (Emax: 10.6 vs 15.6 to acetylcholine (ACh), p < 0.0001 and Emax: 14.6 vs 20.5 to sodium nitroprusside (SNP), p < 0.0001). In hypospadias, testosterone (Emax: 137.9 vs 107.2, p = 0.01) and 17β-estradiol (Emax: 156.9 vs 23.6, p < 0.0001) reduced contraction. Androgens, but not 17β-estradiol, increased endothelium-dependent and endothelium-independent vasorelaxation in cases (Emax: 77.3 vs 51.7 with testosterone, p = 0.02 and vs 48.2 with DHT to ACh, p = 0.0001; Emax: 43.0 vs 39.5 with testosterone, p = 0.02 and vs 39.6 vs 37.5 with DHT to SNP, p = 0.04).
CONCLUSION CONCLUSIONS
In healthy boys, testosterone and 17β-estradiol promote a vasoconstrictor phenotype whereas in boys with hypospadias, these sex hormones reduce vasoconstriction, with androgens promoting vasorelaxation. Differences in baseline artery function may therefore be sex hormone independent and the impact of early-life variations in androgen exposure on vascular function needs further study.

Identifiants

pubmed: 37672642
pii: 7261683
doi: 10.1210/clinem/dgad525
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : British Heart Foundation
ID : CH/12/4/29762
Pays : United Kingdom

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

Auteurs

Angela K Lucas-Herald (AK)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.
Developmental Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Augusto C Montezano (AC)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.
Research Institute of McGill University Health Center, McGill University, 1001 Boul Décarie, Montréal, H4A 3J1, Canada.

Rheure Alves-Lopes (R)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.

Laura Haddow (L)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.

Stuart O'Toole (S)

Department of Pediatric Surgery, Royal Hospital for Children, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Martyn Flett (M)

Department of Pediatric Surgery, Royal Hospital for Children, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Boma Lee (B)

Department of Pediatric Surgery, Royal Hospital for Children, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

S Basith Amjad (SB)

Department of Pediatric Surgery, Royal Hospital for Children, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Mairi Steven (M)

Department of Pediatric Surgery, Royal Hospital for Children, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Jane McNeilly (J)

Developmental Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.
Department of Clinical Biochemistry, Queen Elizabeth University Hospital, Glasgow, G45 8TF.

Katriona Brooksbank (K)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.

Rhian M Touyz (RM)

Institute of Cardiovascular and Medical Sciences, British Heart Foundation Center for Research Excellence, University of Glasgow, 126 University Avenue, Glasgow, G12 8TA, UK.
Research Institute of McGill University Health Center, McGill University, 1001 Boul Décarie, Montréal, H4A 3J1, Canada.

S Faisal Ahmed (SF)

Developmental Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Royal Hospital for Children, 1345 Govan Road, Glasgow, G45 8TF, UK.

Classifications MeSH